SCOR has announced a collaboration with Life Science company Bayer and One Drop, a leader in digital solutions for people living with diabetes and other chronic conditions, to bring One Drop’s AI-powered digital health platform to life insurance carriers and policyholders across the United States.
This joint effort between SCOR, Bayer and One Drop aims to empower people to proactively manage their health through innovative products and to reduce the risk of life-threatening complications from medical conditions. It brings together SCOR’s in-depth knowledge of the insurance sector and its predictive risk assessment underwriting engine, VELOGICA®, One Drop’s fully personalized support experience and predictive capabilities, and Bayer’s expertise in the worldwide development and commercialization of health solutions. By incorporating One Drop into a chronic condition-based insurance solution, SCOR intends to improve its underwriting insights while promoting healthier lifestyles.
“We are excited to bring the latest state-of-the art digital diabetes management functionality to our life insurance clients and their policyholders, empowering policyholders to manage their chronic conditions efficiently,” said Brona Magee, Deputy CEO of SCOR Global Life. “Research suggests that 29.1 million people in the United States have diabetes and around 1.4 million new cases are diagnosed every year. We believe that empowering patients to manage their chronic conditions can both improve lives and help make life insurance more accessible, thereby providing peace of mind.”
A central element of the collaboration is SCOR’s automated underwriting solution, VELOGICA® - an advanced algorithm that delivers superior customer journeys by smoothing the pathway to purchase. VELOGICA® uses highly sophisticated automation that mimics the thought processes of human underwriters, which means the end consumer can get an instant insurance offer. It includes predictive analytics-based underwriting that uses advanced data science techniques to identify data characteristics most likely to produce outcomes.
The partners will develop a customized life insurance solution that pairs SCOR’s VELOGICA® with One Drop’s evidence-based holistic health programs - delivered entirely through the award-winning mobile app. For people living with diabetes and other chronic conditions, One Drop provides a preventative self-care solution by combining asynchronous coaching, health data tracking, and AI-powered health predictions that provide the right interventions at the right times.
“Aligning the power of proactive prevention with those that have incentives to drive long-term health is crucial to advancing preventative care versus expensive reactive care. Working together with SCOR and Bayer represents an exciting opportunity to bring our expertise to even more people and advance our mission of transforming health, changing lives, and creating new opportunities for everyone,” said Jeff Dachis, One Drop CEO and founder.
“Bringing together our know-how with that of SCOR and One Drop is an important milestone in Bayer’s strategic pursuit to build new and innovative digital business models,” said Jeanne Kehren, Head of Digital and Commercial Innovation and Member of the Executive Committee of Bayer Pharma. “Data-based approaches that focus on the person, not the disease, empower them to effectively influence their healthcare to an unprecedented extent.”
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com.